Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
1.510
-0.090 (-5.63%)
At close: Apr 23, 2026, 4:00 PM EDT
1.510
0.00 (0.00%)
Pre-market: Apr 24, 2026, 4:19 AM EDT
Invivyd Revenue
In the year 2025, Invivyd had annual revenue of $53.43M with 110.47% growth. Invivyd had revenue of $17.21M in the quarter ending December 31, 2025, with 24.51% growth.
Revenue (ttm)
$53.43M
Revenue Growth
+110.47%
P/S Ratio
7.99
Revenue / Employee
$437,918
Employees
122
Market Cap
427.03M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 53.43M | 28.04M | 110.47% |
| Dec 31, 2024 | 25.38M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 418.63M |
| REGENXBIO | 170.44M |
| Ginkgo Bioworks Holdings | 170.16M |
| XOMA Royalty | 52.15M |
| Entrada Therapeutics | 25.42M |
| Armata Pharmaceuticals | 4.90M |
| Altimmune | 41.00K |
| vTv Therapeutics | 17.00K |
IVVD News
- 3 days ago - Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit - GlobeNewsWire
- 14 days ago - Invivyd Stock Surges As FDA Alignment Boosts COVID-19 Program - Benzinga
- 14 days ago - Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles - GlobeNewsWire
- 17 days ago - Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 24 days ago - Invivyd Announces Presentation at the World Vaccine Congress Washington - GlobeNewsWire
- 7 weeks ago - Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates - GlobeNewsWire
- 7 weeks ago - Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer - GlobeNewsWire
- 7 weeks ago - Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026 - GlobeNewsWire